1. B11 Targeting the Nrf2 pathway in Huntington's disease: fumaric acid esters as a new therapeutic option in neurodegeneration?. (16th November 2010) Authors: Ellrichmann, G; Lee, D-H; Reick, C; Arning, L; Petrasch-Parwez, E; Saft, C; Gold, R; Linker, R A Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 81(2010)Supplement 1 Page Start: A14 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P07 Astrocytes affect neuroprotection: glatiramer acetate in Huntington's disease therapy. (29th August 2012) Authors: Reick, C; Saft, C; Linker, RA; Wiese, S; Gold, R; Ellrichmann, G Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P08 Analysis of Nrf2-downstream targets after fumarate treatment in dorsal root ganglia—an anti-inflammatory therapy in neurodegenerative disease?!. (29th August 2012) Authors: Ellrichmann, G; Reick, C; Gold, R; Nitsch, R; Saft, C; Linker, RA; Vogelaar, CA Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 83(2012)Supplement 1 Page Start: A54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗